Abstract
The clinical efficacy, safety and usefulness of biapenem (BIPM), a new carbapenem antibiotic for injection, were evaluated in chronic respiratory tract infections in a comparative study with imipenem/cilastatin (IPM/CS) Patients were given 600 mg (potency) of BIPM or 1, 000mg (potency)/1000 mg of IPM/CS daily (b.i.d.) for 14 days, and the following results were obtained: 1. A total of 203 cases were enrolled in this study, and 185 cases were evaluated for clinical efficacy Efficacy rates were 90.3%(84/93) in the BIPM group and 83.7% (77/92) in the IPM/CS group, with no significant difference between the two groups. 2. Bacteriological eradication rates were 70.9% (39/55) in the BIPM group and 66.7% (34/51) in the IPM/CS group, with no significant difference between the two groups. 3. The incidence of adverse reaction was 2.1% (2/95) in the BIPM group and 4.1% (4/98) in the IPM/CS group. There was no significant difference between the two groups. The incidence of abnormal laboratory findings was 20.9% (19/91) in the BIPM group and 21.1% (19/90) in the IPM/CS group. There was no significant difference between the two groups. 4. The usefulness rates were 90.3% (84/93) in the BIPM group and 81.7% (76/93) in the IPM/CS group. There was no significant difference between the two groups. No significant differences were observed between 600 mg (potency) of BIPM and 1, 000mg (potency)/1, 000mg of IPM/CS daily (b.i.d.) with respect to any of the above parameters. These results indicate that BIPM is useful for the treatment of chronic respiratory tract infections.
Original language | English |
---|---|
Pages (from-to) | 63-84 |
Number of pages | 22 |
Journal | Japanese Journal of Chemotherapy |
Volume | 43 |
Issue number | 1 |
DOIs | |
Publication status | Published - 1995 |
Externally published | Yes |
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)